Drugs that contain Fostamatinib Disodium
1. Drug name - TAVALISSE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8211889 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(3 years from now) | |
| US7538108 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Mar, 2026
(3 years from now) | |
| US7989448 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(3 years from now) | |
| US8163902 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(3 years from now) | |
| US7449458 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Sep, 2026
(3 years from now) | |
| CN101115761A | RIGEL PHARMS INC | Prodrug Of 2, 4-Pyrimidinediamine Compound And Its Application |
Jan, 2026
(3 years from now) | |
| CN101115761B | RIGEL PHARMS INC | 2, 4 Compound Of The Prodrug And Its Application |
Jan, 2026
(3 years from now) | |
| IN200702400P2 | RIGEL PHARMS INC | Prodrugs Of 2,4-Pyrimidinediamine Compounds And Their Uses |
Jan, 2026
(3 years from now) | |
| IN262177B | RIGEL PHARMS INC | 2,4-Pyrimidinediamine Compounds |
Jan, 2026
(3 years from now) | |
| EP1856135A1 | RIGEL PHARMS INC | Prodrugs Of 2,4-Pyrimidinediamine Compounds And Their Uses |
Jan, 2026
(3 years from now) | |
| EP1856135B1 | RIGEL PHARMS INC | Prodrugs Of 2,4-Pyrimidinediamine Compounds And Their Uses |
Jan, 2026
(3 years from now) | |
| EP2078026A1 | RIGEL PHARMS INC | Prodrug Salts Of 2, 4-Pyrimidinediamine Compounds And Their Uses |
Nov, 2027
(5 years from now) | |
| EP2078026B1 | RIGEL PHARMS INC | Prodrug Salts Of 2, 4-Pyrimidinediamine Compounds And Their Uses |
Nov, 2027
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266912 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(3 years from now) | |
| USRE48898 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(3 years from now) | |
| US8445485 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(3 years from now) | |
| US8912170 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(3 years from now) | |
| US9283238 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(3 years from now) | |
| US8652492 | RIGEL PHARMS INC | Wet granulation using a water sequestering agent |
Nov, 2028
(6 years from now) | |
| US8263122 | RIGEL PHARMS INC | Wet granulation using a water sequestering agent |
Nov, 2030
(8 years from now) | |
| US8771648 | RIGEL PHARMS INC | (Trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(9 years from now) | |
| US8951504 | RIGEL PHARMS INC | (trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(9 years from now) | |
Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 100MG BASE | TABLET;ORAL | Prescription |
| EQ 150MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.